Enliven Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Enliven Therapeutics generated cash of -$61,269,000, which is less than the previous year. Cash used in financing activities reached the amount of $234,286,000 last year. Net change in cash is therefore $24,605,000.
Cash Flow
| 2017 | -8.78M | 0 | 11M |
|---|---|---|---|
| 2018 | -8.77M | 0 | 6.48M |
| 2019 | -21.87M | -24.06M | 43.57M |
| 2020 | -8.52M | -461K | 130.51M |
| 2021 | -19.13M | -191K | -1.01M |
| 2022 | -32.07M | -612K | -1.79M |
| 2023 | -61.26M | -148.41M | 234.28M |
ELVN Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 75.59M | 110.07M | 130.41M | 8.89M | 7.38M | 9.67M | 7.45M |
Operating activities | |||||||
Net income | -71.58M | -37.66M | -24.74M | -18.96M | -23.46M | -11.33M | 0 |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 297K | 215K | 115K | 45K | 33K | 0 | 0 |
Stock-based compensation expense | 12.91M | 3.19M | 1.92M | 130K | 899K | 555K | 0 |
| Deferred income tax benefit | 12.91M | 3.19M | 1.92M | 130K | 899K | 555K | 0 |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -2.25M | 411K | 1.73M | 291K | 750K | 477K | -666K |
Cash generated by operating activities | -61.26M | -32.07M | -19.13M | -8.52M | -21.87M | -8.77M | -8.78M |
Investing activities | |||||||
Purchases Of Investments | -268.26M | -35M | -47.55M | -64.20M | -23.92M | 0 | 0 |
Investments In Property Plant And Equipment | -149K | -612K | -191K | -461K | -140K | 0 | 0 |
Acquisitions Net | 0 | 35M | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -148.41M | -612K | -191K | -461K | -24.06M | 0 | 0 |
Financing activities | |||||||
Common Stock Issued | 161.20M | 591K | 690K | 140K | 45.57M | 0 | 11M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -226K | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | -1.99M | 0 | 0 |
Cash used in financing activities | 234.28M | -1.79M | -1.01M | 130.51M | 43.57M | 6.48M | 11M |
Net Change In Cash | 24.60M | -34.48M | -20.34M | 121.52M | -2.44M | -2.28M | 2.21M |
Cash at end of period | 100.19M | 75.59M | 110.07M | 130.41M | 4.93M | 7.38M | 9.67M |
| Data source | Data source |